Rethinking the composition of a rational antibiotic arsenal for the 21st century

Future Medicinal Chemistry

Volumn 5, Issue 11, 2013, Pages 1231-1242

  Riley, Margaret A ^a   Robinson, Sandra M ^a   Roy, Christopher M ^a   Dorit, Robert L ^b  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b SMITH COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIOCIN; COLICIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERIOPHAGE; CLINICAL MEDICINE; DRUG DESIGN; DRUG MANUFACTURE; GERM THEORY OF DISEASE; HOST PATHOGEN INTERACTION; HUMAN; MICROBIOME; MINIMUM INHIBITORY CONCENTRATION; PATHOGENESIS; PHYLOGENY; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BACTERIOCINS; BACTERIOPHAGES; COLICINS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; IMIDAZOLES; NIACIN; URINARY TRACT INFECTIONS;

EID: 84891284792     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.79     Document Type: Review

References (134)

1. Fischbach MA, Walsh CT. Antibiotics for emerging pathogens. Science 325(5944), 1089-1093 (2009).
2. Nugent R, Back E, Beith A. The Race Against Drug Resistance: A Report of the Center for Global Development's Drug Resistance Working Group. Center for Global Development, Washington, DC, USA (2010).
3. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century-A clinical super-challenge. N. Engl. J. Med. 360(5), 439-443 (2009).
4. Bush K, Courvalin P, Dantas G, et al.: Tackling antibiotic resistance. Nat. Rev. Microbiol. 9(12), 894-896 (2011).
5. Levy SB, Marshall B. Antibacterial resistance worldwide: Causes, challenges and responses. Nat. Med. 10(12 Suppl.), S122-S129 (2004).
6. Livermore DM. Bacterial resistance: Origins, epidemiology, and impact. Clin. Infect. Dis. 36, S11-S23 (2003).
7. Pitout JDD, Laupland KB. Extended-spectrum b-lactamase-producing Enterobacteriaceae: An emerging public-health concern. Lancet Infect. Dis. 8(3), 159-166 (2008).
8. Mainous Iii AG, Pomeroy C. Management of Antimicrobials in Infectious Diseases: Impact of Antibiotic Resistance. Humana Press, MD, USA (2010).
9. Goff DA. Antimicrobial stewardship: Bridging the gap between quality care and cost. Curr. Opin. Infect. Dis. 24(Suppl. 1), S11-S20 (2011).
10. Roberts RR, Hota B, Ahmad I, et al.: Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: Implications for antibiotic stewardship. Clin. Infect. Dis. 49(8), 1175-1184 (2009).
11. FDA Guidelines for Industry. The Judicious Use of Medically Important Antimicrobial Drugs in Food-Producing Animals. FDA. Silver Spring, MD, USA (2010).
12. Andremont A, Bonten M, Kluytmans J, Carmeli Y, Cars O, Harbarth S. Fighting bacterial resistance at the root: Need for adapted EMEA guidelines. Lancet Infect. Dis. 11(1), 6-8 (2011).
13. Barbosa TM, Levy SB. The impact of antibiotic use on resistance development and persistence. Drug Resist. Updat. 3(5), 303-311 (2000).
14. Guidance for Industry. The Judicious Use of Medically Important Antimicrobial Drugs in Food-Producing Animals 209. FDA, MD, USA (2012).
15. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards Jr. JE. Trends in antimicrobial drug development: Implications for the future. Clin. Infect. Dis. 38(9), 1279-1286 (2004).
16. Dethlefsen L, Mcfall-Ngai M, Relman DA. An ecological and evolutionary perspective on human-microbe mutualism and disease. Nature 449(7164), 811-818 (2007).
17. Gordon JI, Ley RE, Wilson R, et al.: Extending Our View of Self: The Human Gut Microbiome Initiative (HGMI). White Paper (2005).
18. Cotter PD, Ross RP, Hill C. Bacteriocins-A viable alternative to antibiotics? Nat. Rev. Microbiol. 11(2), 95-105 (2012).
19. Li Y, Xiang Q, Zhang Q, Huang Y, Su Z. Overview on the recent study of antimicrobial peptides: Origins, functions, relative mechanisms and application. Peptides 37(2), 207-215 (2012).
20. Riley MA. Bacteriocins, biology, ecology, and evolution. In: Encyclopedia of Microbiology. Schaechter M (Ed.). Elsevier, Oxford, UK, 32-44 (2009).
21. Riley MA, Goldstone CM, Wertz JE, Gordon D. A phylogenetic approach to assessing the targets of microbial warfare. J. Evol. Biol. 16(4), 690-697 (2003).
22. Riley MA, Wertz JE. Bacteriocins: Evolution, ecology, and application. Annu. Rev. Microbiol. 56, 117-137 (2002).
23. Braun V, Pilsl H, Gross P. Colicins: Structures, modes of action, transfer through membranes, and evolution. Arch. Microbiol. 161(3), 199-206 (1994).
24. Konisky J. Colicins and other bacteriocins with established modes of action. Annu. Rev. Microbiol. 36, 125-144 (1982).
25. Tagg JR, Dajani AS, Wannamaker LW. Bacteriocin of Gram-positive bacteria. Bacteriol. Rev. 40(3), 722-756 (1976).
26. Pugsley AP. The ins and outs of colicins. Part I: Production and translocation across membranes. Microbiol. Sci. 1(7), 168-175 (1984).
27. Klaenhammer TR. Bacteriocins of lactic acid bacteria. Biochimie 70(3), 337-349 (1988).
28. Sang Y, Blecha F. Antimicrobial peptides and bacteriocins: Alternatives to traditional antibiotics. Anim. Health Res. Rev. 9(2), 227-235 (2008).
29. Arihara K, Ogihara S, Mukai T, Itoh M, Kondo Y. Salivacin 140, a novel bacteriocin from Lactobacillus salivarius subsp. salicinius T140 active against pathogenic bacteria. Lett. Appl. Microbiol. 22(6), 420-424 (1996).
30. Riley MA, Pinou T, Wertz JE, Tan Y, Valletta CM. Molecular characterization of the klebicin B plasmid of Klebsiella pneumoniae. Plasmid 45(3), 209-221 (2001).
31. Wertz JE, Riley MA. Chimeric nature of two plasmids of hafnia alvei encoding the bacteriocins alveicins A and B. J. Bacteriol. 186(6), 1598-1605 (2004).
32. Riley MA, Robinson SM, Roy CM, Dennis M, Liu V, Dorit RL. Resistance is futile: The bacteriocin model for addressing the antibiotic resistance challenge. Biochem. Soc. Trans. 40(6), 1438-1442 (2012).
33. Gouaux E. The long and short of colicin action: The molecular basis for the biological activity of channel-forming colicins. Structure 5(3), 313-317 (1997).
34. Riley MA. Molecular mechanisms of bacteriocin evolution. Annu. Rev. Genet. 32, 255-278 (1998).
35. Sano Y, Kobayashi M, Kageyama M. Functional domains of S-Type pyocins deduced from chimeric molecules. J. Bacteriol. 175(19), 6179-6185 (1993).
36. Svetoch EA, Levchuk VP, Pokhilenko VD, et al.: Inactivating methicillin-resistant Staphylococcus aureus and other pathogens by use of bacteriocins OR-7 and E 50-52. J. Clin. Microbiol. 46(11), 3863-3865 (2008).
37. Eijsink VG, Skeie M, Middelhoven PH, Brurberg MB, Nes IF. Comparative studies of class IIa bacteriocins of lactic acid bacteria. Appl. Environ. Microbiol. 64(9), 3275-3281 (1998).
38. Mohankumar A, Murugalatha N. Characterization and antibacterial activity of bacteriocin producing lactobacillus isolated from raw cattle milk sample. Int. J. Biol. 3(3), 128-143 (2011).
39. Papagianni M, Avramidis N, Filioussis G, Dasiou D, Ambrosiadis I. Determination of bacteriocin activity with bioassays carried out on solid and liquid substrates: Assessing the factor 'indicator microorganism'. Microb. Cell Fact. 5, 30 (2006).
40. Sifour M, Tayeb I, Haddar HO, Namous H, Aissaoui S. Production and characterization of bacteriocin of Lactobacillus plantarum F12 with inhibitory activity against Listeria monocytogenes. J. Sci. Technol. 2(1), 55-61 (2012).
41. US Food and Drug Administration. Nisin preparation: Affirmation of GRAS status as a direct human food ingredient. Fed. Regist. 53, 11247-11251 (1988).
42. Ansari A, Aman A, Siddiqui NN, Iqbal S, Ali Ul Qader S. Bacteriocin (BAC-IB17): Screening, isolation and production from Bacillus subtilis KIBGE IB-17. Pak. J. Pharm. Sci. 25(1), 195-201 (2012).
43. Belguesmia Y, Madi A, Sperandio D, et al.: Growing insights into the safety of bacteriocins: The case of enterocin S37. Res. Microbiol. 162(2), 159-163 (2011).
44. Bhunia AK, Johnson MC, Ray B, Belden EL. Antigenic property of pediocin AcH produced by Pediococcus acidilactici H. J. Appl. Bacteriol. 69(2), 211-215 (1990).
45. Cladera-Olivera F, Caron GR, Brandelli A. Bacteriocin-like substance production by Bacillus licheniformis strain P40. Lett. Appl. Microbiol. 38(4), 251-256 (2004).
46. De Vuyst L, Leroy F. Bacteriocins from lactic acid bacteria: Production, purification, and food applications. J. Mol. Microbiol. Biotechnol. 13(4), 194-199 (2007).
47. O'Sullivan L, Ross RP, Hill C. Potential of bacteriocin-producing lactic acid bacteria for improvements in food safety and quality. Biochimie 84(5-6), 593-604 (2002).
48. Martirani L, Varcamonti M, Naclerio G, De Felice M. Purification and partial characterization of bacillocin 490, a novel bacteriocin produced by a thermophilic strain of Bacillus licheniformis. Microb. Cell Fact. 1(1), 1 (2002).
49. Bhunia AK, Johnson MC, Ray B, Belden EL. Antigenic property of pediocin AcH produced by Pediococcus acidilactici H. J. Appl. Microbiol. 69(2), 211-215 (2008).
50. Brahmachary M, Krishnan SPT, Koh JLY, et al.: ANTIMIC: A database of antimicrobial sequences. Nucleic Acids Res. 32(Suppl. 1), D586-D589 (2004).
51. De Kwaadsteniet M, Doeschate KT, Dicks LM. Nisin F in the treatment of respiratory tract infections caused by Staphylococcus aureus. Lett. Appl. Microbiol. 48(1), 65-70 (2009).
52. Hancock REW, Chapple DS. Peptide antibiotics. Antimicrob. Agents Chemother. 43(6), 1317-1323 (1999).
53. Ingham A, Ford M, Moore RJ, Tizard M. The bacteriocin piscicolin 126 retains antilisterial activity in vivo. J. Antimicrob. Chemother. 51(6), 1365-1371 (2003).
54. Sutyak KE, Wirawan RE, Aroutcheva AA, Chikindas ML. Isolation of the Bacillus subtilis antimicrobial peptide subtilosin from the dairy product-derived Bacillus amyloliquefaciens. J. Appl. Microbiol. 104(4), 1067-1074 (2008).
55. Castiglione F, Cavaletti L, Losi D, et al.: A novel lantibiotic acting on bacterial cell wall synthesis produced by the uncommon actinomycete Planomonospora sp
56. Maher S, Mcclean S. Investigation of the cytotoxicity of eukaryotic and prokaryotic antimicrobial peptides in intestinal epithelial cells in vitro. Biochem. Pharmacol. 71(9), 1289-1298 (2006).
57. Cursino L, Smajs D, Smarda J, et al.: Exoproducts of the Escherichia coli strain H22 inhibiting some enteric pathogens both in vitro and in vivo. J. Appl. Microbiol. 100(4), 821-829 (2006).
58. Dicks L, Knoetze H, Van Reenen C. Otitis Media: A review, with a focus on alternative treatments. Probiotics Antimicrob. Proteins 1(1), 45-59 (2009).
59. Montalban-Lopez M, Sanchez-Hidalgo M, Valdivia E, Martinez-Bueno M, Maqueda M. Are bacteriocins underexploited? Novel applications for old antimicrobials. Curr. Pharm. Biotechnol. 12(8), 1205-1220 (2011).
60. Riley MA. Molecular mechanisms of colicin evolution. Mol. Biol. Evol. 10(6), 1380-1395 (1993).
61. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human infections. Bacteriophage 1(2), 66-85 (2011).
62. Carlton RM. Phage therapy: Past history and future prospects. Arch. Immunol. Ther. Exp. (Warsz.) 47(5), 267-274 (1999).
63. Kutter E, De Vos D, Gvasalia G, et al.: Phage therapy in clinical practice: Treatment of human infections. Curr. Pharm. Biotechnol. 11(1), 69-86 (2010).
64. Stratton CW. Dead bugs don't mutate: Susceptibility issues in the emergence of bacterial resistance. Emerg. Infect. Dis. 9(1), 10-16 (2003).
65. Abedon S. Bacteriophages and Biofilms: Ecology, Phage Therapy, Plaques. Nova Science Publishers, NY, USA (2010).
66. Skurnik M, Pajunen M, Kiljunen S. Biotechnological challenges of phage therapy. Biotechnol. Lett. 29(7), 995-1003 (2007).
67. Alisky J, Iczkowski K, Rapoport A, Troitsky N. Bacteriophages show promise as antimicrobial agents. J. Infect. 36(1), 5-15 (1998).
68. Górski A, Borysowski J, Miedzybrodzki R, Weber-Dabrowska B. Bacteriophages in medicine. In: Genetics and Microbiology. Grath SM, Sinderen DV (Eds). Caister Academic Press, Norfolk, UK, 125-158 (2007).
69. Kutateladze M, Adamia R. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol. 28(12), 591-595 (2010).
70. Mann NH. The potential of phages to prevent MRSA infections. Res. Microbiol. 159(5), 400-405 (2008).
71. Matsuda T, Freeman TA, Hilbert DW, et al.: Lysis-deficient bacteriophage therapy decreases endotoxin and inflammatory mediator release and improves survival in a murine peritonitis model. Surgery 137(6), 639-646 (2005).
72. Payne RJ, Jansen VA. Pharmacokinetic principles of bacteriophage therapy. Clin. Pharmacokinet. 42(4), 315-325 (2003).
73. Rhoads DD, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS, Sulakvelidze A. Bacteriophage therapy of venous leg ulcers in humans: Results of a Phase I safety trial. J. Wound Care 18(6), 237-238, 240-233 (2009).
74. Budynek P, Dabrowska K, Skaradzinski G, Gorski A. Bacteriophages and cancer. Arch. Microbiol. 192(5), 315-320 (2010).
75. Duerr DM, White SJ, Schluesener HJ. Identification of peptide sequences that induce the transport of phage across the gastrointestinal mucosal barrier. J. Virol. Methods 116(2), 177-180 (2004).
76. Gorski A, Wazna E, Dabrowska BW, Dabrowska K, Switala-Jelen K, Miedzybrodzki R. Bacteriophage translocation. FEMS Immunol. Med. Microbiol. 46(3), 313-319 (2006).
77. Merril C. Interaction of bacteriophages with animals. In: Bacteriophage Ecology. Abedon S (Ed.). Cambridge University Press, Cambridge, UK, 332-352 (2008).
78. Sulakvelidze A. Phage therapy: An attractive option for dealing with antibiotic-resistant bacterial infections. Drug Discov. Today 10(12), 807-809 (2005).
79. Sulakvelidze A, Alavidze Z, Morris Jr. JG. Bacteriophage therapy. Antimicrob. Agents Chemother. 45(3), 649-659 (2001).
80. Duckworth DH, Gulig PA. Bacteriophages: Potential treatment for bacterial infections. BioDrugs 16(1), 57-62 (2002).
81. Weber-Dabrowska B, Dabrowski M, Slopek S. Studies on bacteriophage penetration in patients subjected to phage therapy. Arch. Immunol. Ther. Exp. (Warsz.) 35(5), 563-568 (1987).
82. Weber-Dabrowska B, Mulczyk M, Gorski A. Bacteriophage therapy of bacterial infections: An update of our institute's experience. Arch. Immunol. Ther. Exp. (Warsz.) 48(6), 547-551 (2000).
83. Weber-Dabrowska B, Mulczyk M, Górski A. Bacteriophages as an efficient therapy for antibiotic-resistant septicemia in man. Transplant. Proc. 35(4), 1385-1386 (2003).
84. Wright A, Hawkins CH, Anggard EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol. 34(4), 349-357 (2009).
85. Nederberg F, Zhang Y, Tan JP, et al.: Biodegradable nanostructures with selective lysis of microbial membranes. Nat. Chem. 3(5), 409-414 (2011).
86. Zhang L, Pornpattananangku D, Hu CM, Huang CM. Development of nanoparticles for antimicrobial drug delivery. Curr. Med. Chem. 17(6), 585-594 (2010).
87. Yanagihara K, Tashiro M, Fukuda Y, et al.: Effects of short interfering RNA against methicillin-resistant Staphylococcus aureus coagulase in vitro and in vivo. J. Antimicrob. Chemother. 57(1), 122-126 (2006).
88. Lopez-Fraga M, Wright N, Jimenez A. RNA interference-based therapeutics: New strategies to fight infectious disease. Infect. Disord. Drug Targets 8(4), 262-273 (2008).
89. Giamarellos-Bourboulis EJ, Bolanos N, Laoutaris G, et al.: Immunomodulatory intervention in sepsis by multidrug-resistant Pseudomonas aeruginosa with thalidomide: An experimental study. BMC Infect. Dis. 5, 51 (2005).
90. Hancock RE, Nijnik A, Philpott DJ. Modulating immunity as a therapy for bacterial infections. Nat. Rev. Microbiol. 10(4), 243-254 (2012).
91. Zucca M, Savoia D. The post-Antibiotic era: Promising developments in the therapy of infectious diseases. Int. J. Biomed. Sci. 6(2), 77-86 (2010).
92. Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Sahm DF. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob. Agents Chemother. 46(8), 2540-2545 (2002).
93. Kunin CM. Antibiotic armageddon. Clin. Infect. Dis. 25(2), 240-241 (1997).
94. Hamilton-Miller JM. 'Think like a bacterium': A helpful concept to prolong the antibiotic era? Clin. Microbiol. Infect. 4(4), 177-178 (1998).
95. Stickler DJ. Bacterial biofilms in patients with indwelling urinary catheters. Nat. Clin. Pract. Urol. 5(11), 598-608 (2008).
96. Brumfitt W, Hamilton-Miller JM. Efficacy and safety profile of long-Term nitrofurantoin in urinary infections: 18 years' experience. J. Antimicrob. Chemother. 42(3), 363-371 (1998).
97. Harding GK, Ronald AR. The management of urinary infections: What have we learned in the past decade? Int. J. Antimicrob. Agents 4(2), 83-88 (1994).
98. Stamm WE, Norrby SR. Urinary tract infections: Disease panorama and challenges. J Infect. Dis. 183(Suppl. 1), S1-S4 (2001).
99. Yilmaz N, Agus N, Yurtsever SG, et al.: Prevalence and antimicrobial susceptibility of Escherichia coli in outpatient urinary isolates in Izmir, Turkey. Med. Sci. Monit. 15(11), PI61-PI65 (2009).
100. Foxman B. Epidemiology of urinary tract infections: Incidence, morbidity, and economic costs. Dis. Mon. 49(2), 53-70 (2003).
101. Hooton TM. Pathogenesis of urinary tract infections: An update. J. Antimicrob. Chemother. 46(Suppl. A), 1-7 (2000).
102. Hooton TM, Stamm WE. Diagnosis and treatment of uncomplicated urinary tract infection. Infect. Dis. Clin. North Am. 11(3), 551-581 (1997).
103. Warren JW. Catheter-Associated urinary tract infections. Infect. Dis. Clin. North Am. 11(3), 609-622 (1997).
104. Felmingham D, Arakawa S. Resistance among urinary tract pathogens: Experience outside the USA. Clin. Drug Invest. 21, 7-11 (2001).
105. Gupta K, Hooton TM, Stamm WE. Increasing antimicrobial resistance and the management of uncomplicated community-Acquired urinary tract infections. Ann. Intern. Med. 135(1), 41-50 (2001).
106. Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: The ECO.SENS project. J. Antimicrob. Chemother. 51(1), 69-76 (2003).
107. Mazzulli T. Resistance trends in urinary tract pathogens and impact on management. J. Urol. 168(4 Pt 2), 1720-1722 (2002).
108. Murray BE, Alvarado T, Kim KH, et al.: Increasing resistance to trimethoprim-sulfamethoxazole among isolates of Escherichia coli in developing countries. J. Infect. Dis. 152(6), 1107-1113 (1985).
109. Seifert R, Weinstein DM, Li-Mcleod J. National prevalence of Escherichia coli resistance to trimethoprim-sulfamethoxazole: Managed care implications in the treatment of urinary tract infections. J. Manag. Care Pharm. 7(132), (2001).
110. Talan DA, Stamm WE, Hooton TM, et al.: Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: A randomized trial. JAMA 283(12), 1583-1590 (2000).
111. Miller LG, Tang AW. Treatment of uncomplicated urinary tract infections in an era of increasing antimicrobial resistance. Mayo Clin. Proc. 79(8), 1048-1053 (2004).
112. Nickel JC. Management of urinary tract infections: Historical perspective and current strategies: Part 1-before antibiotics. J. Urol. 173(1), 21-26 (2005).
113. Gupta V, Yadav A, Joshi RM. Antibiotic resistance pattern in uropathogens. Ind. J. Med. Microbiol. 20(2), 96-98 (2002).
114. Raz R, Chazan B, Kennes Y, et al.: Empiric use of trimethoprim- sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin. Infect. Dis. 34(9), 1165-1169 (2002).
115. Henker J, Laass M, Blokhin BM, et al.: The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers. Eur. J. Pediatr. 166(4), 311-318 (2007).
116. Henker J, Laass MW, Blokhin BM, et al.: Probiotic Escherichia coli Nissle 1917 versus placebo for treating diarrhea of greater than 4 days duration in infants and toddlers. Pediatr. Infect. Dis. J. 27(6), 494-499 (2008).
117. Reid G, Bruce AW. Probiotics to prevent urinary tract infections: The rationale and evidence. World J. Urol. 24(1), 28-32 (2006).
118. Storm DW, Koff SA, Horvath Jr. DJ. Li B, Justice SS. In vitro analysis of the bactericidal activity of Escherichia coli Nissle 1917 against pediatric uropathogens. J. Urol. 186(4 Suppl.), 1678-1683 (2011).
119. Abad CL, Safdar N. The role of lactobacillus probiotics in the treatment or prevention of urogenital infections-A systematic review. J. Chemother. 21(3), 243-252 (2009).
120. Budic M, Rijavec M, Petkovsek ZI, Gur-Bertok DZ. Escherichia coli bacteriocins: Antimicrobial efficacy and prevalence among isolates from patients with bacteraemia. PLoS ONE 6(12), e28769 (2011).
121. Rijavec M, Budic M, Mrak P, Muller-Premru M, Podlesek Z, Zgur-Bertok D. Prevalence of ColE1-like plasmids and colicin K production among uropathogenic Escherichia coli strains and quantification of inhibitory activity of colicin K. Appl. Environ. Microbiol. 73(3), 1029-1032 (2007).
122. Shanks RM, Dashiff A, Alster JS, Kadouri DE. Isolation and identification of a bacteriocin with antibacterial and antibiofilm activity from Citrobacter freundii. Arch. Microbiol. 194(7), 575-587 (2012).
123. Smith K, Martin L, Rinaldi A, Rajendran R, Ramage G, Walker D. Activity of pyocin S2 against Pseudomonas aeruginosa biofilms. Antimicrob. Agents Chemother. 56(3), 1599-1601 (2012).
124. Trautner BW, Hull RA, Darouiche RO. Prevention of catheter-Associated urinary tract infection. Curr. Opin. Infect. Dis. 18(1), 37-41 (2005).
125. Drew RH, Arthur RR, Perfect Jr. Is it time to abandon the use of amphotericin B bladder irrigation? Clin. Infect. Dis. 40, 1465-1470 (2005).
126. Waites KB, Canupp KC, Roper JF, Camp SM, Chen Y. Evaluation of 3 methods of bladder irrigation to treat bacteriuria in persons with neurogenic bladder. J. Spinal Cord Med. 29(3), 217-226 (2006).
127. Brand AM, De Kwaadsteniet M, Dicks LM. The ability of nisin F to control Staphylococcus aureus infection in the peritoneal cavity, as studied in mice. Lett. Appl. Microbiol. 51(6), 645-649 (2010).
128. Chatterjee S, Chatterjee DK, Jani RH, et al.: Mersacidin, a new antibiotic from Bacillus. In vitro and in vivo antibacterial activity. J. Antibiot. (Tokyo) 45(6), 839-845 (1992).
129. Fontana MB, De Bastos Mdo C, Brandelli A. Bacteriocins Pep5 and epidermin inhibit Staphylococcus epidermidis adhesion to catheters. Curr. Microbiol. 52(5), 350-353 (2006).
130. Goldstein BP, Wei J, Greenberg K, Novick R. Activity of nisin against Streptococcus pneumoniae, in vitro, and in a mouse infection model. J. Antimicrob. Chemother. 42(2), 277-278 (1998).
131. Kruszewska D, Sahl HG, Bierbaum G, Pag U, Hynes SO, Ljungh A. Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model. J. Antimicrob. Chemother. 54(3), 648-653 (2004).
132. Mota-Meira M, Morency H, Lavoie MC. In vivo activity of mutacin B-Ny266. J. Antimicrob. Chemother. 56(5), 869-871 (2005).
133. Niu WW, Neu HC. Activity of mersacidin, a novel peptide, compared with that of vancomycin, teicoplanin, and daptomycin. Antimicrob. Agents Chemother. 35(5), 998-1000 (1991).
134. Van Staden AD, Brand AM, Dicks LM. Nisin F-loaded brushite bone cement prevented the growth of Staphylococcus aureus in vivo. J. Appl. Microbiol. 112(4), 831-840 (2012).